Regulatory expectations for understanding product impurities and degradants in biopharmaceuticals continue to increase, and many biopharmaceutical developers are finding their “current” CMC methods are quickly becoming obsolete. New, highly sensitive and specific technologies are now emerging from R&D into the QC lab and are becoming the “new normal.” But how do you address heightened regulatory expectations while managing the risk associated with mid-course changes to methods?
Join us for 60 minutes of discussion on how to bring your program to current technologies with confidence.
Register Now on Contract Pharma's website!
Speaker:
Glenn Petrie, Ph. D.
Senior Scientific Advisor
ABC Laboratories
excel in this job and scale the career heights.follow this link
ReplyDelete